Investor
DC Funds, LP
CIK 0001869028 · filed 2026-05-14 · SEC filing
13F book
$1.49M
Positions
3
Largest name
42.4%
TScan Therapeutics, Inc. · TCRX
Est. mark
$33.1K
Price effect on 3 names still held. Flow −$0.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| TScan Therapeutics, Inc. | TCRX | 630K | $630K | 42.4% | $0 | Held |
| Werewolf Therapeutics, Inc. | HOWL | 589.1K | $490.5K | 33.0% | $117.3K | Held |
| Barinthus Biotherapeutics Pl | — | 642.2K | $365.4K | 24.6% | −$84.2K | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.